| Description |
BMS-433771 is a potent orally active inhibitor of respiratory syncytial virus (RSV). BMS-433771 is active against both A and B groups of RSV, with an average EC50 of 20 nM. BMS-433771 can be used for the research of respiratory tract disease[1][2].
|
| Related Catalog |
|
| Target |
EC50: 20 nM (RSV)[1]
|
| In Vitro |
BMS-433771 has inhibitory against both A and B groups of RSV, with an average EC50 of 20 nM[1]. BMS-433771 can inhibit viral F protein-induced membrane fusion[1].
|
| In Vivo |
BMS-433771 (p.o.; 1-200 mg/kg; single or bid 4 days) shows prophylactic efficacy via oral dosing，but has considerable pharmacodynamic differences between the two rodent models[2] . Animal Model: rodent models of RSV infection[2] (cotton rat and mice) Dosage: 1, 10, and 50 mg/kg (mice); 25, 50, 100, and 200 mg/kg (rat) Administration: oral, single or bid 4 days Result: Had prophylactic efficacy via oral dosing in both animal models. Showed RSV infection more sensitive to inhibition in the BALB/c mouse host than in the cotton rat.
|
